Stockreport

KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported [Yahoo! Finance]

Kineta, Inc.  (KA) 
PDF No dose limiting toxicities observed at any dose level Cleared fifth of six monotherapy cohorts and second of four combination cohorts Kineta is actively exploring [Read more]